Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $1.3 million.

  • Heron Therapeutics' Free Cash Flow fell 5472.79% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.1 million, marking a year-over-year decrease of 24698.61%. This contributed to the annual value of -$24.2 million for FY2024, which is 5983.19% up from last year.
  • Latest data reveals that Heron Therapeutics reported Free Cash Flow of $1.3 million as of Q3 2025, which was down 5472.79% from -$11.1 million recorded in Q2 2025.
  • Heron Therapeutics' Free Cash Flow's 5-year high stood at $2.9 million during Q3 2024, with a 5-year trough of -$63.3 million in Q2 2021.
  • For the 5-year period, Heron Therapeutics' Free Cash Flow averaged around -$24.1 million, with its median value being -$25.1 million (2023).
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Free Cash Flow was 12948.26% (2024), while the steepest drop was 66317.46% (2024).
  • Quarter analysis of 5 years shows Heron Therapeutics' Free Cash Flow stood at -$45.6 million in 2021, then grew by 16.87% to -$37.9 million in 2022, then surged by 105.81% to $2.2 million in 2023, then crashed by 663.17% to -$12.4 million in 2024, then soared by 110.72% to $1.3 million in 2025.
  • Its Free Cash Flow stands at $1.3 million for Q3 2025, versus -$11.1 million for Q2 2025 and -$9.0 million for Q1 2025.